Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 5.0 %

Shares of Evoke Pharma stock opened at $2.10 on Friday. The business has a 50-day moving average price of $3.60 and a 200 day moving average price of $4.41. Evoke Pharma has a fifty-two week low of $1.94 and a fifty-two week high of $12.32. The firm has a market cap of $3.14 million, a P/E ratio of -0.19 and a beta of 0.30.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.24). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The business had revenue of $3.31 million during the quarter, compared to analyst estimates of $3.08 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC grew its position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the SEC.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.